Harnessing Artificial Intelligence for Disease Detection and Rapid Drug Discovery: A Path to Accelerated Medical Responses
Abstract
The history of Artificial Intelligence (AI) in drug discovery spans decades, from rule-based systems to sophisticated machine learning and deep learning algorithms. Early applications included virtual screening and QSAR modeling, which paved the way for data-driven drug development. Today, systems like IBM Watson Health and DeepMind's AlphaFold are good at analyzing medical data, predicting molecular interactions, and accelerating the design of novel drugs. Yet in most AI solutions that already exist, they usually only solve the specific tasks rather than formulating a comprehensive framework in emerging disease management. This paper proposes the integration of disease symptom data, pathogen-level analysis, and treatment prediction via an AI-driven model about diseases with symptoms such as cold, cough, or fever. The system correlates new pathogens with stored datasets and identifies potential medicine combinations for rapid testing and refinement, thereby significantly reducing the timelines for drug development. Hence, this approach addresses the severe need for scalable, fast-response solutions in managing infectious diseases and future pandemics.
Metrics
References
M. Subramanian, A. Wojtusciszyn, L. Favre, S. Boughorbel, J. Shan, K.B. Letaief, N. Pitteloud, L. Chouchane, Precision medicine in the era of artificial intelligence: implications in chronic disease management. Journal of Translational Medicine, 18(1), (2020). https://doi.org/10.1186/s12967-020-02658-5
M. Raparthi, S.R. Gayam, V.S.P. Nimmagadda, M.K. Sahu, S. Putha, S.P. Pattyam, K.K. Kondapaka, B.P. Kasaraneni, P. Thuniki, S.S. Kuna, AI Assisted Drug Discovery: emphasizing its role in accelerating precision medicine initiatives and improving treatment outcomes. Human-Computer Interaction Perspectives, 2(2), (2022) 1-10.
Z. Liu, R.A. Roberts, M. Lal-Nag, X. Chen, R. Huang, W. Tong. Drug Discovery Today. AI-based Language Models Powering Drug Discovery and Development. Drug Discovery Today, 26(11), (2021) 2593–2607. https://doi.org/10.1016/j.drudis.2021.06.009
R. Gupta, D. Srivastava, M. Sahu, S. Tiwari, R.K. Ambasta, P. Kumar, Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Molecular Diversity, 25(3), (2021) 1315–1360. https://doi.org/10.1007/s11030-021-10217-3
N. Terranova, K. Venkatakrishnan, Machine Learning in Modeling Disease Trajectory and Treatment Outcomes: An Emerging enabler for Model‐Informed Precision Medicine. Clinical Pharmacology & Therapeutics, 115(4), (2023) 720–726. https://doi.org/10.1002/cpt.3153
Y. Park, D. Casey, I. Joshi, J. Zhu, F. Cheng, Emergence of new disease: How can artificial intelligence help? Trends in Molecular Medicine, 26(7), (2020) 627–629. https://doi.org/10.1016/j.molmed.2020.04.007
G. Alterovitz, W. Alterovitz, G.H. Cassell, L. Zhang, A.K. Dunker, AI for infectious disease modelling and therapeutics. Biocomputing, (2020) 91–94. https://doi.org/10.1142/9789811232701_0009
S. Vatansever, A. Schlessinger, D. Wacker, H.U. Kaniskan, J. Jin, M. Zhou, B. Zhang, Artificial intelligence and machine learning‐aided drug discovery in central nervous system diseases: State‐of‐the‐arts and future directions. Medicinal Research Reviews, 41(3), (2020) 1427–1473. https://doi.org/10.1002/med.21764
Google Health AI. (2020). AI for medical imaging and disease detection. IBM Watson Health. (2020). AI-powered healthcare solutions. BenevolentAI. (2020). AI
Copyright (c) 2025 Lavanya M, Harshini V.S
This work is licensed under a Creative Commons Attribution 4.0 International License.
Views: Abstract : 83 | PDF : 63
Plum Analytics
.png){kind=logo}
.png)
.png)
.png)
